Zosurabalpin targets drug-resistant bacteria behind sepsis and pneumonia

A potential game-changer in the fight against deadly hospital infections is entering the final stage of human trials. Swiss pharmaceutical giant Roche announced it is moving forward with Phase 3 testing of its experimental antibiotic, zosurabalpin, a drug designed to combat highly drug-resistant infections that threaten millions each year.

Jointly developed with Harvard University, Zosurabalpin will be tested specifically against Acinetobacter baumannii — a dangerous pathogen that the U.S. Centers for Disease Control and Prevention (CDC) has labeled an “urgent threat” due to its resistance to current treatments. Notably, it’s been more than half a century since the last effective antibiotic was developed to treat infections caused by this microbe.

A silent killer: the global burden of sepsis and pneumonia

Hospital-acquired infections such as pneumonia and sepsis continue to exact a staggering human toll. Sepsis alone is responsible for 11 million deaths annually — roughly one person every 2.8 seconds — while community-acquired pneumonia (CAP) kills up to four million people each year, disproportionately affecting older adults with pre-existing health conditions.

Drive into the Future with the 2025 Subaru Forester

drive into the future with the 2025 subaru forester...

May 28, 2025

1:26 pm

Need a new Car? Rent To Own Cars No Credit Check

need a new car? rent to own cars no credit check ...

May 28, 2025

1:14 pm

Explore Surprisingly Affordable Luxury RAM 1500

explore surprisingly affordable luxury ram 1500...

May 28, 2025

1:21 pm

2025 Jeep Wrangler Price One Might Not Want to Miss!

2025 jeep wrangler price one might not want to miss!...

May 28, 2025

1:30 pm

Zosurabalpin’s success could mark a critical turning point in modern medicine’s battle against antimicrobial resistance (AMR), a growing threat that undermines decades of medical progress.

Global clinical trial begins with hope for end-of-decade approval

The Phase 3 clinical trial will enroll approximately 400 patients from diverse global locations, Roche said. The goal is to evaluate the efficacy and safety of the drug in treating severe infections where conventional antibiotics often fail.

“Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health,” said Michael Lobritz, Roche’s global head of infectious diseases, in a statement to The Independent.

Want an SUV with Easy Access and Comfort for Seniors? Here’s How to Get It!

want an suv with easy access and comfort for seniors? here’s how to get it!...

May 28, 2025

1:27 pm

Celebrate the Holidays in a New Hyundai Palisade

celebrate the holidays in a new hyundai palisade...

May 28, 2025

1:14 pm

Explore The 2025 Jeep Compas: Adventure Awaits!

explore the 2025 jeep compas: adventure awaits!...

May 28, 2025

1:19 pm

Drive into the Future with the 2025 Subaru Forester

drive into the future with the 2025 subaru forester...

May 28, 2025

1:25 pm

Larry Tsai, senior vice president and global head of immunology at Roche’s infectious disease unit, emphasized the scale of the crisis. “These drug-resistant bacteria are present in every country of the world,” Tsai noted. “The innovative biology involved in this research could potentially reveal new insights into the structure of bacterial membranes, possibly leading to the discovery of new antibiotics in the future.”

A potential milestone in the post-antibiotic era

Zosurabalpin’s development reflects renewed urgency in pharmaceutical innovation following years of stagnation in antibiotic research. Public health experts have long warned that without effective new antibiotics, the world could face a “post-antibiotic era” where routine surgeries and minor infections once again become fatal.

If successful, zosurabalpin could be approved for public use by the end of the decade, potentially saving millions of lives and ushering in a new era of antimicrobial treatment.

This article New lifesaving antibiotic to fight sepsis and pneumonia enters final human testing phase appeared first on BreezyScroll.

Read more on BreezyScroll.